NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 33.5% in January

NextCure, Inc. (NASDAQ:NXTC) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 55,000 shares, a growth of 33.5% from the January 15th total of 41,200 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 158,000 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on shares of NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a report on Monday, November 11th.

Institutional Investors Weigh In On NextCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in NextCure by 27.9% during the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after buying an additional 113,300 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in NextCure during the 4th quarter valued at about $311,000. Finally, Geode Capital Management LLC lifted its holdings in NextCure by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after buying an additional 27,812 shares in the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Stock Up 4.5 %

NXTC traded up $0.03 on Friday, reaching $0.76. 33,479 shares of the company traded hands, compared to its average volume of 75,547. NextCure has a one year low of $0.66 and a one year high of $2.57. The firm has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $1.20. The company has a market cap of $21.21 million, a P/E ratio of -0.36 and a beta of 0.66.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.